Tumor Microenvironment Triggered Cascade‐Activation Nanoplatform for Synergistic and Precise Treatment of Hepatocellular Carcinoma
- 28 February 2021
- journal article
- research article
- Published by Wiley in Advanced Healthcare Materials
- Vol. 10 (10) , 2002036
Abstract
Hepatocellular carcinoma (HCC) is one of the most common and deadliest malignancy cancers, which remains a major global health problem. At present, over 50% of patients with HCC have implemented systemic therapies, such as interventional therapy or local chemotherapy that are scarcely effective and induce serious side effects to the remaining normal liver, further limiting their clinical outcomes. Herein, a tumor microenvironment triggered cascade‐activation nanoplatform (A‐NPLap/TPZ) is prepared based on β‐lapachone (β‐Lap) and tirapazamine (TPZ) for the synergistic therapy of HCC. The A‐NPLap/TPZ exerts its targeting effect by binding to the receptor of tumor cells with an external aptamer. In the tumor microenvironment, the nanoplatform can realize H2O2‐triggered disassembly to release β‐Lap and TPZ. The released β‐Lap generates ROS to induce tumor cell apoptosis under the catalysis of the tumor cell over‐expressed NAD(P)H‐quinone oxidoreductase‐1 (NQO1) enzyme. In this process, oxygen is consumed to intensify tumor hypoxia, and eventually cascade activates TPZ to exert the anti‐tumor effect. The studies in vitro and in vivo consistently demonstrate that the as‐prepared A‐NPLap/TPZ nanoplatform possesses an excellent synergistic anti‐tumor effect. This design of nanoplatform with cascade activation effect provides a promising strategy for HCC treatment.Keywords
Funding Information
- National Natural Science Foundation of China (61727823, 61905043, 81871483)
- Natural Science Foundation of Fujian Province (2018J01146)
This publication has 49 references indexed in Scilit:
- Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatmentEuropean Journal of Pharmaceutics and Biopharmaceutics, 2014
- Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivoInternational Journal of Nanomedicine, 2014
- Ultrasensitive Nanosensors Based on Upconversion Nanoparticles for Selective Hypoxia Imaging in Vivo upon Near-Infrared ExcitationJournal of the American Chemical Society, 2014
- An H2O2-responsive nanocarrier for dual-release of platinum anticancer drugs and O2: controlled release and enhanced cytotoxicity against cisplatin resistant cancer cellsChemical Communications, 2014
- Hepatocellular carcinoma: clinical frontiers and perspectivesGut, 2014
- Prodrug Strategy to Achieve Lyophilizable, High Drug Loading Micelle Formulations Through Diester Derivatives of β‐LapachoneAdvanced Healthcare Materials, 2014
- Targeting hypoxia in cancer therapyNature Reviews Cancer, 2011
- Uptake and cytotoxicity of chitosan nanoparticles in human liver cellsToxicology and Applied Pharmacology, 2010
- β-Lapachone Micellar Nanotherapeutics for Non–Small Cell Lung Cancer TherapyCancer Research, 2010
- Metabolism of tirapazamine by multiple reductases in the nucleus11Abbreviations: TPZ, tirapazamine; P450 reductase, NADPH:cytochrome P450 reductase; PMSF, phenylmethylsulfonyl fluoride; DTT, dithiothreitol; DHR123, dihydrorhodamine 123; DAPI, 4′,6-diamidino-2-phenylindole, dihydrochloride; SN, supernatant from nuclei; LS, low salt; HS, high salt; and NM, nuclear matrix.Biochemical Pharmacology, 2001